In future research, we hope to improve the concordance between core needle biopsy tissue and traditional surgery tissue by optimizing the procedure through multifocal needle puncture, and then add genomic testing such as OncotypeDX and MammaPrint to our prediction model through prospective research, so as to predict the benefit of NCT in HR+/HER2− breast cancer patients more accurately. The gene discussed is HR; the disease is breast carcinoma.